10.8 C
Munich
Friday, March 24, 2023
Home Blog Page 3

Vemanti Group Inc (OTCMKTS: VMNT) Making Moves as Fintech Enters Framework SaaS Agreement with Finastra & Looks to Uplist Shares

Vemanti Group Inc (OTCMKTS: VMNT) has been on the move northbound in recent days on a surge of buy volume and not much selling, VMNT has rocketed over $0.30 per share and highs near $0.40. This comes after the Company filed an 8k on March 9 stating it has entered into a Framework SaaS Agreement with Finastra International Limited that will only become effective upon Vemanti Group’s shares being listed on the Nasdaq Capital Market on or before May 22, 2023, and will have a term of seven years. 

VMNT is no stranger to big runs; during most of 2020 and leading into 2021, VMNT saw a historic rise from pennies to over $2.50 per share. The Company operates as a financial partner for SMEs throughout Southeast Asia, helping their business become borderless and together shaping the region into a global economic powerhouse, especially in Vietnam, which is booming right now. Vemanti has also secured a up to $2 million investment from Alpha Sigma Capital Fund, LP signaling a major collaborative step forward for the two companies. We will be updating on VMNT when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Vemanti Group Inc (OTCMKTS: VMNT) operating out of Irvine, California is a financial technology (fintech) company that seeks to establish a strong foothold in the emerging and high-growth markets of Southeast Asia. Vemanti drives growth through socially impact-driven financial services targeting the underserved. Strategically, the Company intends to focus future product and business development on building a digital banking (aka neobanking) platform aimed at making credit and cross-border payments simpler and easier for Small and Medium-sized Enterprises (SMEs). With Vietnam as the focal starting point, Vemanti’s goal is to be a valuable financial partner for the SMEs throughout Southeast Asia, helping their business become borderless and together shaping the region into a global economic powerhouse of growing supply chains and manufacturing. Back during the summer of 2021 Vemanti formed Vemanti Digital Ltd and deployed an Ethereum smart contract for a US Dollar-backed, fully reserved, stablecoin named Vemanti USD however the Company abandoned the coin and later burned the tokens. 

VMNT was founded in 2014 by its CEO Tan Tran, bringing more than 25 years of seasoned high-tech industry experience. Prior to founding Vemanti Group, Mr. Tran worked at various leading technology companies including Western Digital, SMC Networks, Sync Research, Alcatel-Lucent, Veraz Networks, GenBand, Fronde, Metaswitch Networks, and Exalt Communications. He was featured in local Vietnamese business publications as an up-and-coming tech entrepreneur to watch. Since founding VMNT, Tan has worked to turn Vemanti Group into an investment and incubation platform for emerging companies with great growth potential, especially in Vietnam which continues to be an economic force on both a regional and global scale. 

VoiceStep which was founded in 2005 by Mr. Tran and his old business partner Mark Wehberg, is a one-stop solution with regard to business-class VoIP services to its small to medium-sized business customers in the United States. On January 22, 2014, Mr. Tran purchased the membership interest in VoiceStep owned by Mr. Wehberg. VoiceStep provides a cloud-based multi-location, multi-user, enterprise-grade communications solution that enables employees to communicate through voice, text, web conferencing, and fax on devices, including smartphones, tablets, PCs, and desk phones. It offers PBX features such as multiple extensions, call control, Outlook integration, SM, telephony conferencing; fax, auto-receptionist, call logs and rule-based call routing and answering. The Company also has the ability to deliver customized voice applications to meet a customer’s business requirements. The entire switching infrastructure of VoiceStep is based on next-generation softswitch architecture and was engineered in-house from the ground up. This eliminates certain dependency on third-party vendors and, at the same time, allows the company greater technical flexibility and economic scalability.  

 To Find out the inside Scoop on VMNT Subscribe to newsytrends.com Right Now by entering your Email in the box below

VMNT

VoiceStep offers business-class VoIP products such as cloud phone systems (aka hosted PBX) and domestic/International origination and termination as a cost-saving and profit-increasing solution to multi-location enterprise customers. The Company is capable of delivering business-class VoIP solutions in all 50 States as well as in Canada and other countries where VoIP applications are allowed. VoiceStep’s network enables the following technology solutions: unified communications, data center services, content delivery, VoIP and cloud computing. 

The Company acquired a 20% interest in Fvndit, f/k/a Directus Holdings, Inc., which owns eLoan, JSC for $300k consisting of $150k in cash and $150k in Vemanti stock.  Due to dilution the Company’s 20% stake is now an 18.6% interest in Fvndit. Through its subsidiaries, Fvndit operates an online short-term P2P financing platform for SMEs in Vietnam. Fvndit’s mission is to make borrowing through credit a simpler process for entrepreneurs, thus making investing more rewarding for investors. Its wholly owned subsidiary eLoan, which was launched in 2017, operates an online P2P funding platform that matches investors with entrepreneurs, allowing anyone on the platform to fund short-term working capital directly to SMEs in Vietnam.  

According to the 8k filed on March 9, on March 3 Vemanti entered into a Framework SaaS Agreement with Finastra International Limited, a limited corporation organized under the laws of Wales and the United Kingdom. The SaaS Agreement will only become effective upon the Company’s shares being listed on the Nasdaq Capital Market on or before May 22, 2023 and will have a term of seven years. If the Company is not successful in having its shares listed on the Nasdaq Capital Market on or before May 22, 2023, the SaaS Agreement has no force and effect. If the SaaS Agreement becomes effective, Finastra will license its software and provide development services, SaaS services, maintenance services and other services to the Company for between $325k to $550k per year. 

 We have something big coming Subscribe Right Now!

Currently trading at a $20 million market valuation VMNT os is 70,524,209 with around 31,037,000 shares in the public float. Vemanti is OTCQB and an SEC filer and has less than a million in assets on the books, very little debt and minimal revenues to date. VMNT is an exciting story developing in small caps; Vemanti operates as a financial partner for SMEs throughout Southeast Asia, helping their business become borderless and together shaping the region into a global economic powerhouse, especially in Vietnam, which is booming right now. Another strategy Vemanti employs is to acquire companies and/or form joint ventures. The Company focuses on helping smaller companies accelerate their growth, execute their business plans and then scale up from there. Vemanti has a team assembled for the express purpose of sourcing attractive investment and M&A opportunities, developing and scaling them, and then building valuation for Vemanti shareholders. We will be updating on VMNT when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in VMNT either long or short and we have not been compensated for this article.

VNUE Inc (OTCMKTS: VNUE) On Watch as Ambitious CEO Retains ICON for Captial Raise and Uplist (More on Soundstr & Music Royalty)

VNUE Inc (OTCMKTS: VNUE) has been on the move northbound in recent days and the volume and price have increased substantially. The move comes as the Company has recently partnered with Kokku, South America’s largest gaming and entertainment co-development firm, to bring a continuous VNUE Festival and multi-stage experience on Roblox (NYSE: RBLX) in Q1 of 2023. Additionally, VNUE has retained ICON Capital Group to raise $15MM or more, in order to list onto the NADSAQ Stock Market. The Company is led by CEO Zach Bair a music industry executive who has sold Company’s to Mark Cuban and EMC Corp. 

Also, on March 16 VNUE retained Boca Ratan-based securities law firm, Hamilton & Associates Law Group, P. A. to facilitate VNUE’s planned uplist to NASDAQ. Led by founder and partner Brenda Hamilton, the law firm will draft the Registration Statement and required U.S. securities law disclosures for the uplist to NASDAQ and a $15MM to $20MM capital raise. Bringing the VNUE festival to Roblox’s more than 50 million active users worldwide is Phase One of the company’s plan. VNUE is the Company behind Soundstr™ – a music identification and rights management Cloud platform currently making a move on the $10 billion global music royalty business. VNUE UPDATE: is up over 50% on Monday and is closing in on a penny with 16 million shares traded as of 2pm on Monday.  We will be updating on VNUE when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

VNUE Inc (OTCMKTS: VNUE) is a multi-faceted music technology company dedicated to monetizing the live music experience for artists, labels, writers, and publishers, with products such as its set.fm instant content distribution platform set.fm exclusive license partner and “instant live” pioneer DiscLive disclive.net and protecting the rights of artists and writers with the company’s Soundstr music recognition technology (MRT) soundstr.com. The veteran entrepreneurs, artists and songwriters behind VNUE, led by music and tech entrepreneur and recording artist Zach Bair are passionate about the future of their industry and ensuring that rights holders’ value is not lost amid always-changing technology. 

VNUE also recently acquired StageIt one of the oldest and most well-known ticketed livestreaming platforms. VNUE now has the ability to livestream concerts and other events, adding to the pool of other live music focused technology services. Stage It is an established platform where concerts or other live events may be ticketed (just like an in-person event), and fans who pay for tickets may enjoy a performance or other engagement by watching digital video as it occurs on their web browser. For example, an artist can create an event through the platform, and then, in advance, let their fans know they can purchase the ability to view the concerts on the Stage It platform. Fans then buy the ability to access these concerts, and at the designated time, the fan may then observe the live performance on Stage It.com. Recently Director of Wolf Entertainment, Hellmut Wolf, joins forces with StageIt as Director of International Artist Acquisitions. The partnership expands StageIt’s coverage not only in Europe, but Africa and Australia as well. 

Set.fm™ / DiscLive Network™ – is the Company’s consumer app platform allowing customers to download and purchase, via their individual mobile device, the concert they just attended. There are also physical collectible products which are recorded and sold at shows as well as online through the Company’s exclusive partner DiscLive Network™. The app itself is free to download and allows for in app purchases regarding the content.  

Soundstr™ – is the Company’s comprehensive music identification and rights management Cloud platform that we are developing, when fully deployed, can accurately track and audit public performances of music, creating a more transparent ecosystem for general music licensing and associated royalty payments, which will help ensure the correct stakeholders are compensated through the use of its “big data” collection. 

To Find out the inside Scoop on VNUE Subscribe to Newsytrends.com Right Now by entering your Email in the box below

VNUE

RobloxRecently VNUE began working with South American Premiere Roblox developer Kokku to build the first ever persistent multi-stage music & entertainment festival experience which will initially be deployed on Roblox’s platform, with 50+ Million active daily users worldwide. Kokku is the developer best known for its work on AAA games such as Guerrilla’s Horizon franchise, Activision’s Call of Duty: Black Ops – Cold War, and Premium Roblox Experiences including Samsung’s Space Tycoon and Netflix’ Stranger Things: Starcourt Mall. Known as the “VNUE Icon Project” a.k.a. “VIP,” is getting closer to launch date, as the one of multiple planned virtual festival Arenas stands at approximately 90% completion. 

VNUE Festival Entertainment Space – The VNUE festival will operate continuously, presenting both free and ticketed concerts, music launches, listening parties and more each day across multiple themed and customizable stages. Fans will experience interactive games, missions, eMerch as well as parental controls for Roblox’s young audience. Partners, sponsors, and official music curators will be announced in coming months. 

Zach Bair - CEO, Chairman @ VNUE - Crunchbase Person ProfileZach Bair, CEO of VNUE, said, “The ICON project is coming along nicely and as expected. Key components, such as our ‘Earth Arena’ – one of multiple virtual arenas – are at 95% completion; Earth Mini Games elements and other features are through their incremental build process and are awaiting our approvals. I’m very satisfied with the pace at which production is being accomplished, and I can’t wait for this exciting technology to be rolled out.” 

 

For More on VNUE Subscribe Right Now!

Currently trading at a $7.5 million market valuation VNUE os is 1,723,606,272 with around 1,237,512,931 shares in the public float. While the Company does carry a significant amount of debt on the books its assets and revenues continue to grow. VNUE is an exciting story developing in small caps; The Company is led by ambitious CEO Zach Bair a music industry executive who has sold Company’s to Mark Cuban and EMC Corp. Recently VNUE retained Boca Ratan-based securities law firm, Hamilton & Associates Law Group, P. A. to facilitate VNUE’s planned uplist to NASDAQ. Led by founder and partner Brenda Hamilton, the law firm will draft the Registration Statement and required U.S. securities law disclosures for the uplist to NASDAQ and a $15MM to $20MM capital raise. Bringing the VNUE festival to Roblox’s more than 50 million active users worldwide is Phase One of the company’s plan. VNUE is the Company behind Soundstr™ – a music identification and rights management Cloud platform currently making a move on the $10 billion global music royalty business.  We will be updating on VNUE when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in VNUE either long or short and we have not been compensated for this article.

Viaderma Inc (OTCMKTS: VDRM) Red Hot as Biotech Relaunches Vitastem and Vitastem Ultra & Awaits FDA Registration Status Approval for Nupelo

Viaderma Inc (OTCMKTS: VDRM) is an exciting biotech currently making a big move up the charts in recent weeks from a start point off its 52-week lows of $0.044 VDRM has rocketed over a penny and is now moving up in copperland. The move up comes as Viaderma continues to put out solid news reporting earlier this week the Company has submitted its application for its planned minoxidil hair regrowth product for FDA registration status approval. The FDA registration process should be relatively quick, and the Company expects this process to be completed within a few weeks. 

VDRM saw a huge run back in early 2021 from well under a penny to highs over $0.07 and investors are looking for a return to these levels. The Company continues to make progress recently launching two new and improved formulas for its top selling product, Vitastem and Vitastem Ultra. Viaderma also expanded its licensing agreement with a large wound care network. The licensee recently increased the number of states in which they operate to eleven. ViaDerma receives $5,000 per month for each state in which the licensee is doing business and the new states increases ViaDerma’s current royalties to $55,000 per month from this agreement. We will be updating on VDRM when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Viaderma Inc (OTCMKTS: VDRM) is a specialty pharmaceutical company committed to bringing the best new products to market through many years of innovative clinical research, testing & product development. ViaDerma licenses products in the fields of medicine ranging from infectious diseases to wound care, skin care, CBD, cosmetics, and more. In addition to licensing our proprietary transdermal technologies, our lead product Vitastem is available for treating multiple skin conditions & ailments. Lots of things are happeninng at VDRM including a new corporate website here: ViaDerma.com.  

ViaDerma’s lead product Vitastem utilizes an innovative transdermal delivery method to apply any active ingredient to a topical drug. This unique dual carrier transdermal technology can be applied into products within the medical and cosmetics markets. Vitastem is one of the best and most powerful topical antibiotics in the world. With over 10 years of rigorous clinical testing, multiple patents, and more – ViaDerma has produced the most advanced transdermal delivery system that treats numerous infectious diseases far better and faster than any products currently on the market. Recently the Company launched a new and improved formula for Vitastem that is clear and colorless compared to the brownish color of the original, so it will not stain the skin, fingernails, toenails, or anywhere else it is applied. 

ViaDerma’s other product Vitastem Ultra uses bacitracin instead of tetracycline. This provides an alternative for people who are allergic to tetracycline, as well as a way to treat tetracycline resistant bacteria. Additionally, Vitastem Ultra will open new doors overseas in many markets that prefer tetracycline alternatives. Like the new and improved Vitastem, Vitastem Ultra is colorless and non-staining. Batches of the new products are currently being produced and are expected to be available to consumers on Amazon, Vitastem.net and other ViaDerma resellers by mid-October.  

ViaDerma’s unique transdermal delivery system facilitates the transfer of chemicals through the stratum corneum, the outermost layer of the skin with a diffusion constant that is 10,000x higher than other products on the market. This allows much more of the active ingredient to be absorbed into the skin and work better and faster, often producing significantly better results than traditional topical treatments.  

ViaDerma (@viaderma) / TwitterRecently ViaDerma expanded its licensing agreement with a large wound care network. The licensee recently increased the number of states in which they operate to eleven. Per the agreement, ViaDerma receives $5,000 per month for each state in which the licensee is doing business. The addition of the new states increases ViaDerma’s current royalties to $55,000 per month from this agreement. The wound care network has indicated their intent to add new states at a more rapid pace and believes they can be nationwide within the next twelve months.

To Find out the inside Scoop on VDRM Subscribe to Newsytrends.com Right Now by entering your Email in the box below

VDRM

ViaDerma Pharma | LinkedInViaDerma is currently in the process of seeking approval for insurance coverage benefits for Vitastem and Vitastem Ultra. Many insurance companies including Medicare and Medicaid offer over-the-counter benefits (OTC) for non-prescription or OTC products such as the products offered by ViaDerma. 

Earlier in March VDRM launched a new hair regrowth product using Minoxidil. The company will incorporate their proprietary, patent-pending dual carrier transdermal delivery technology with Minoxidil to create their new hair regrowth product. The global hair restoration market as a whole which includes surgical and noninvasive treatments is expected to reach USD 13.6 billion by 2028, according to this research report by Grand View Research. Minoxidil is the active ingredient in several top selling hair regrowth products including Rogaine, Rogaine Extra Strength and Lipogaine. FDA registration of the product is expected to be completed within the next 90 days. The company expects to have the new product on the market later this year.  

The company has chosen Nupelo as the brand name for its new hair regrowth product. ViaDerma plans to make Nupelo available for purchase via several online platforms including their newly acquired domain, nupelo.com. The product is expected to be ready to go to market and available to purchase online by the end of Q2 2023. 

Amazon.com: Christopher Otiko: books, biography, latest updateViaDerma’s President & CEO, Dr. Chris Otiko stated: “Everything has really come together very quickly and smoothly. Due to the extreme effectiveness of our proprietary transdermal delivery system, we are able to develop new products like Nupelo in a very short period of time. Many other hair products only work to reduce hair loss, but are ineffective at actually regrowing hair. Nupelo works to solve both.” 

 For More on VDRM Subscribe Right Now!

Currently trading at a $13 million market valuation VDRM os is 1,023,620,662 with around 911,600,265 shares in the public float. The Company has a decent balance sheet with little assets and $2.5 million in liabilities on the books. VDRM is an exciting story developing in small caps; Viaderma continues to make progress recently launching two new and improved formulas for its top selling product, Vitastem and Vitastem Ultra. Viaderma also expanded its licensing agreement with a large wound care network. The licensee recently increased the number of states in which they operate to eleven. ViaDerma receives $5,000 per month for each state in which the licensee is doing business and the new states increases ViaDerma’s current royalties to $55,000 per month from this agreement. More recently Viaderma submitted its application for its planned minoxidil hair regrowth product for FDA registration status approval. The FDA registration process should be relatively quick, and the Company expects this process to be completed within a few weeks.  We will be updating on VDRM when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in VDRM either long or short and we have not been compensated for this article.

Baudax Bio Inc (NASDAQ: BXRX) Reverses Northbound off New 52 Week Lows as Biotech Advances its Neuromuscular Blocking Agents BX1000, BX2000, & BX3000

0

Baudax Bio Inc (NASDAQ: BXRX) is making a big move up the charts running 44% on Thursday alone after the stock recently reversed off $1.25 lows. BXRX has fallen a long way over the past year as the Company had to take its first commercial product, ANJESO® off the shelves in December. Also, they were forced to dilute the stock and executed a 1 for 40 reverse stock split in December further decimating the share price. 

Now that BXRX has reversed and is moving northbound the stock is once again under accumulation as the Company completes a $4.7 million public offering. Baudax is currently developing an intermediate-acting NMB, BX1000, an ultra- short acting NMB, BX2000, and a reversal agent specific to its NMBs, BX3000. Neuromuscular blocking agents are used as muscle paralyzing agents to facilitate intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation. We will be updating on BXRX when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Baudax Bio Inc (NASDAQ: BXRX) is a pharmaceutical company focused on innovative products for hospitals and related settings. The Company has a pipeline of innovative pharmaceutical assets including two clinical-stage, novel neuromuscular blocking (NMBs) agents, one undergoing a Phase II clinical trial and an additional unique NMB undergoing a dose escalation Phase I clinical trial, as well as a proprietary chemical reversal agent specific to these NMBs, which is currently undergoing nonclinical and manufacturing studies to prepare for an expected IND filing in the summer of 2023. 

Baudax holds exclusive global rights to two new molecular entities, which are centrally acting Neuromuscular Blocking Agents (NMBs), BX1000, an intermediate duration of action NMB currently undergoing a Phase II clinical trial, and BX2000, an ultra-short acting NMB currently undergoing a Phase I clinical trial, as well as a proprietary blockade reversal agent, BX3000, currently being evaluated in preclinical studies intended to support an IND filing in 2023. BX3000 is an agent that is expected to rapidly reverse BX1000 and BX2000 blockade. All three agents are licensed from Cornell University.  

The Company believes these agents, when administered in succession, will allow for a rapid onset of centrally acting neuromuscular blockade, followed by a rapid reversal of the neuromuscular blockade with BX3000. These novel agents have the potential to meaningfully reduce time to onset of blocking and of reversal of blockade, reducing time in operating rooms or post operative suites (PACU), resulting in potential clinical and cost advantages, as well as valuable cost savings for hospitals and ambulatory surgical centers. 

In mid-2020, Baudax launched its first commercial product, ANJESO®, in the United States. ANJESO is the first and only 24-hour, intravenous, or IV, analgesia agent. The Company successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and two Phase IIIb programs evaluating ANJESO’s clinical safety and efficacy along with its positive health economic impacts in specific surgical settings. For now, Baudax has discontinued commercial sales of ANJESO in December of 2022. 

To Find out the inside Scoop on BXRX Subscribe to Newsytrends.com Right Now by entering your Email in the box below

BXRX

In January Baudax reported the successful outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. This randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of rocuronium is planned to enroll a total of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia. The primary efficacy endpoint is the proportion of patients meeting criteria for Good or Excellent intubating conditions using a standardized scale. Additionally, the trial is evaluating the safety and tolerability profile of BX1000 and rocuronium in this patient population. 

Baudax is led by CEO Gerri Henwood, a biotech executive who was the founder and Chief Executive Officer of IBAH, Inc., or IBAH, a contract research organization listed on NASDAQ. Ms. Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline plc. In February Baudax reported its fourth quarter and annual financial results at which time the Company president and CEO Gerri Henwood stated:

“During our fourth quarter we refocused our priorities on our NMB portfolio, initiating our Phase II trial for BX1000 and advancing our Phase I dose escalation trial for BX2000. The encouraging interim data we announced from the BX1000 trial showed all patients treated to date have met the criteria for Good or Excellent intubating conditions at 60 seconds, and that BX1000 has been generally well tolerated. We believe these data speak to the potential of our NMB portfolio to improve patient management and deliver cost efficiencies in procedures where NMB is required. We expect to complete enrollment in the BX1000 trial during the first quarter of 2023, and to announce top line data early in the second quarter of 2023. Concurrently, BX2000, our ultrashort acting NMB, is continuing through its dose escalation study, which we expect to complete by the end of 2023. BX3000, our NMB reversal agent, remains on track, and we expect to complete the nonclinical and manufacturing studies needed to support an IND filing for BX3000, the NMB reversal agent in the summer of 2023. Data from these trials will provide us with insight on the profiles of the two blocking agents, which will contribute to decisions to move forward later in 2023.”

 For More on BXRX Subscribe Right Now!

Currently trading just under $2 after seeing a significant reversal off $1.25 BXRX has fallen a long way over the past year as the Company had to take its first commercial product, ANJESO® off the shelves in December. Also, they were forced to dilute the stock and executed a 1 for 40 reverse stock split in December further decimating the share price. From current levels BXRX is once again under accumulation as the Company completes a $4.7 million public offering. The Company is currently developing an intermediate-acting NMB, BX1000, an ultra- short acting NMB, BX2000, and a reversal agent specific to its NMBs, BX3000. Neuromuscular blocking agents are used as muscle paralyzing agents to facilitate intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.   We will be updating on BXRX when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in BXRX either long or short and we have not been compensated for this article.

Tenax Therapeutics, Inc. (NASDAQ:TENX) Reverses Northbound off New 52 Week Lows as Biotech Advances Lmatinib (TNX-201) & Levosimendan (TNX-102)

Tenax Therapeutics, Inc. (NASDAQ:TENX) recently made a strong reversal off new 52-week lows of $0.45 per share and is currently trading just a little bit higher right over $0.55 per share. The Company currently has two drugs Imatinib (TNX-201) and Levosimendan (TNX-101, TNX-102 and TNX-103) ready to begin phase 3 trials for PAH and pulmonary hypertension with left side heart failure and preserved ejection fraction (PH-HFpEF) respectively.  With a significant naked short position in the stock and trading at a tiny $24 million market valuation TENX is at the top of investors’ watch lists. 

In February Tenax completed a public offering selling 8.67 million shares or pre-funded warrant with associated warrants at $1.80 per unit. Two warrants with an exercise price of $2.25 per share were issued for each underlying equity share or pre-funded warrant. Proceeds will support the clinical development of imatinib and levosimendan for PAH and pulmonary hypertension with left side heart failure and preserved ejection fraction (PH-HFpEF) respectively. In February Tenax was issued a patent covering the use of IV levosimendan in the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). Tenax is currently waiting on the decision on another patent which could be a significant catalyst. Also, any announcement about partnership, funding or acquisition could take TENX far. We will be updating on TENX when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Tenax Therapeutics Inc (NASDAQ: TENX) is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. Tenax Therapeutics is developing a unique oral formulation of imatinib. The Company also owns North American rights to develop and commercialize subcutaneous and oral formulations of levosimendan.  

Tenax products include Imatinib (TNX-201) and Levosimendan (TNX-101, TNX-102 and TNX-103). Tenax is developing novel dosing and a unique formulation of imatinib mesylate, a kinase inhibitor that has received FDA’s orphan designation (March 2020) for the treatment of pulmonary arterial hypertension (PAH). The IMPRES trial, a previous Phase 3 trial, demonstrated that oral imatinib may produce a markedly greater, and much more durable, treatment effect on exercise tolerance, than any other available PAH treatment, alone or in combination, based on the results observed in those patients who were maintained on the full imatinib dose for the majority of the trial. Despite the availability of several classes of pulmonary vasodilators, no existing treatment has been shown to halt progression or induce regression of the disease. Imatinib acts on underlying cellular proliferative pathways associated with PAH and has the potential to be the first disease modifying therapy for PAH. 

To Find out the inside Scoop on TENX Subscribe to Newsytrends.com Right Now by entering your Email in the box below

TENX

Tenax is also developing Levosimendan; a unique potassium ATP channel activator and calcium sensitizer that affects the heart and vascular system through multiple mechanisms of action. Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in over 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure.  

Tenax Therapeutics has North American rights to develop and commercialize IV (TNX-101), subcutaneous (TNX-102), and oral (TNX-103) formulations of levosimendan. Results of Tenax Therapeutics’ Phase 2 trial of levosimendan in patients with pulmonary hypertension (PH) and heart failure with preserved ejection fraction (HFpEF) demonstrated that IV levosimendan produces potent dilation of the central and pulmonary venous circulations which translates into an improvement in exercise capacity, a discovery that forms the basis for the Phase 3 investigation of Tenax Therapeutics’ potential groundbreaking therapy. To date, no other drug therapy has improved exercise tolerance in patients with PH associated with HFpEF, recently referred to as the greatest unmet need in cardiovascular disease. 

 For More on TENX Subscribe Right Now!

Currently trading at a $24 million market valuation TENX os is 44.6 million shares and rising. The Company has a healthy balance sheet as per their latest 10Q with very little debt, only burning about $2.5 million a quarter and quickly advancing clinical trials of imatinib and levosimendan for PAH and pulmonary hypertension with left side heart failure and preserved ejection fraction (PH-HFpEF) respectively. In February the Company raised $15.7 million from its public offering at $1.80 per share. We will be updating on TENX when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in TENX either long or short and we have not been compensated for this article.

Tautachrome Inc (OTCMKTS: TTCM) Big Move as Co Becomes Exclusive Licensee of El Dorado Family Group Intellectual Property Portfolio

Tautachrome Inc (OTCMKTS: TTCM) is making a big move up the charts trading over 100 million shares on Wednesday alone and closing up 55% on the day after the Company announced earlier in the week via an 8k that on March 10, El Dorado Family Group, exchanged a Royalty-Free Grant of Exclusive Use-license of certain intellectual properties for 55,000,000 shares of Fixed Non-Cumulative Nonconvertible Perpetual Preferred Stock from Tautachrome Inc.  El Dorado is controlled by Timothy A. Holly, who is also a director of the Registrant. 

El Dorado Family Group, Ltd., and its subsidiaries, doing business as “Regal Photo Archive” and “Red Alert Media Matrix” has a collection of several million photographic images from newspapers, over 4,100 hours of television programming, and more than 1,000 video clips. The Media Assets are all originals and can never be replaced. Penelope A. Dixon and Associates, inc., a leading appraiser of documentary art determined the maximum insurable value of the Media Assets to be $514,441,340.66. We will be updating on TTCM when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Tautachrome Inc (OTCMKTS: TTCM) operating out of Oro Valley, Arizona operates in the internet applications space, uniquely exploiting the technologies of the Augmented Reality sector, the blockchain/cryptocurrency sector and the smartphone picture and video technology sector. We have high-speed blockchain concepts under development aiming to couple with the Company’s revolutionary patents and licensing in augmented reality, smartphone-image authentication and imagery-based social networking interaction. 

Tautachrome is currently pursuing three main avenues of business activity based on its patented activated imaging technology, its blockchain cryptocurrency products, and its licensing of the patent pending ARk technology. 

KlickZie ARk technology business: The Company has licensed and is developing a new KlickZie augmented reality (“AR”) platform branded ARknet. ARknet enables goods and services providers to establish geolocated augmented reality interfaces, called ARks, allowing consumers to purchase the provider’s products and take advantage of its specials and discounts, using the ARk. A provider’s ARk may be located anywhere in the world, from a store location to anyplace else the provider may desire. The ARknet is a fintech platform connecting consumers to providers in the global $48 trillion household goods market, using augmented reality as the medium of interaction. 

KlickZie’s blockchain cryptocurrency-based ecosystem: The Company has developed its own digital currency (“XAR”), smart contracts using XARs, and high speed blockchain concepts aimed at supporting fast frictionless transactions within the ARknet as well as incentivizing user download and use of KlickZie products. 

KlickZie Activated Digital Imagery business: The Company is developing downloadable apps based on our patented KlickZie trusted imaging technology and based on our patented trusted image-based social interactions using the pictures and videos that smartphone users create. Trusted imagery and user imagery-based interaction is expected to be widely used within the ARknet. 

In January the Company partnered with MetaKeep for the integration of their digital wallet protocol into the ARknet platform. Web3 is still a new space, with your average person having little familiarity with it and with the digital asset universe encompassed by Web3. MetaKeep allows ARknet Platform users to gain the advantages of asset ownership in the digital asset universe transparently, seamlessly and securely. 

To Find out the inside Scoop on TTCM Subscribe to Newsytrends.com Right Now by entering your Email in the box below

TTCM

Penelope Dixon & Associates | LinkedInOn Friday, March 10, 2023, El Dorado Family Group, Ltd. a Georgia corporation, exchanged a Royalty-Free Grant of Exclusive Use-license of certain intellectual properties having appraised value of $514,441,340 for 55,000,000 shares of Fixed Non-Cumulative Nonconvertible Perpetual Preferred Stock from Tautachrome Inc.  El Dorado is controlled by Timothy A. Holly, who is also a director of the Registrant. 

El Dorado Family Group, Ltd., and its subsidiaries, doing business as “Regal Photo Archive” and “Red Alert Media Matrix” has a collection of several million photographic images from newspapers, over 4,100 hours of television programming, and more than 1,000 video clips. The Media Assets are all originals and can never be replaced. Penelope A. Dixon and Associates, inc., a leading appraiser of documentary art determined the maximum insurable value of the Media Assets to be $514,441,340.66. 

 For More on TTCM Subscribe Right Now!

Currently trading at a $5.7 million market valuation TTCM os is 6,383,687,017 with 2,247,243,558 shares in the public float. TTCM is an exciting story developing in small caps, the stock actually hit the bulletin boards after being spun off from a big board several years ago and historically TTCM was highly liquid and had a large following of investors. Currently moving up off its 52-week lows TTCM is heating up and making moves while the overall markets see steep declines. The Company is an SEC filer with convertible debt on the books and minimal revenues to date. We will be updating on TTCM when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in TTCM either long or short and we have not been compensated for this article.

The Gloves Come Off on Winners, Inc. (OTC PINK: WNRS)

Winners, Inc. (OTCMKTS: WNRS) has seen a significant surge in trading volume after WNRS reported the company decided to withdraw its application for a 1:20 reverse split of its common stock with FINRA. The Company withdrew the FINRA application considering its strategic expansion plans that include the increase of its product line and potential acquisitions that fit the company’s business model. This comes several days after the Winners executed an agreement with ClickStream Corp whereby Winners agreed to buy back 154,012,000 shares of Winners common stock owned by ClickStream for $160,265.63. This transaction reduces Winners outstanding shares of common stock from 336,529,857 to 182,517,857. 

According to the Company’s CEO Wayne Allyn Root: “When I started this company my number one mission was aggressive growth. Not only are we expanding our product line but we’re also looking at potential acquisitions that fit our business model. We’ve only just started, and the buyback of the ClickStream shares substantially reduces our outstanding shares of common stock, thereby enhancing shareholder value. While all this does sound good WNRS has been falling since the morning highs suggesting someone is distributing shares. We will be updating on WNRS when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Winners, Inc. (OTC PINK: WNRS) through its subsidiaries is engaged in the business of sports gambling research, data, advice, analysis and predictions utilizing all available media, advertising formats and its database of users. Revenues are expected to accelerate due to the explosion of sports handicapping arising from the 2018 Supreme Court decision that States have the right to approve sports gambling and the resulting State by State rapid approval of sports gambling. Its Subsidiaries:  

VegasWinners is a licensed sports gambling affiliate that intends to drive traffic to gaming operators for commission. VegasWinners is currently licensed in several states and has made applications in additional states. It is the intent of VegasWinners to get licensed in all states that allow online sports gambling. To date online sports gambling has been legalized in; Arizona, Colorado, Connecticut, Illinois, Indiana, Iowa, Kansas, Louisiana, Maryland, Massachusetts, Michigan, Mississippi, Nevada, New Jersey, New York, Ohio, Pennsylvania, Tennessee, Virginia, Washington DC, West Virginia, Wyoming & Ontario.  

Same-game parlays, or SGPs, have emerged as not only one of the most popular bets on the board for bettors but also one of the most profitable for bookmakers. In last year’s Super Bowl, 31% of bets placed before the game kicked off were same-game parlays at BetRivers, Barstool and other U.S. sportsbooks powered by Kambi, an international sports betting platform provider. Prop betting is the act of betting on an event that takes place inside of or during a ga tome or sporting event. Prop bets involve betting on events that take place inside the game but will differ from traditional point spread and total bets that deal only with the final outcome. A better way to think about it is like this.  Live in-game betting is one of the most recent technological advancements in legal sports betting and one that has greatly improved the overall experience of sports betting. Essentially, live betting allows fans to bet on in-game outcomes while the game is being played. 

To Find out the inside Scoop on WNRS Subscribe to newsytrends.com Right Now by entering your Email in the box below

CORZQ

Winners Inc. (@vegaswinnersinc) / TwitterThe global sports betting market accounted for USD 83.65 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 10.3% from 2023 to 2030 as reported by Grand View Research. 

On March 14 WNRS announced it is taking steps to expand its product line of Handicapping Services to include same-game parlays, prop betting and/or in-game sports wagering. Furthermore, the company decided to withdraw its application for a 1:20 reverse split of its common stock with FINRA. The Company withdrew the FINRA application considering its strategic expansion plans that include the increase of its product line and potential acquisitions that fit the company’s business model. 

Wayne Allyn Root, CEO of Winners Inc., stated, “We are currently exploring different options to expand our product line of Handicapping Services which will include same-game parlays, prop betting and/or in-game sports wagering. The expansion of services will add additional revenue streams to the company. Also, we have recently done a buy-back of the outstanding shares by over 50%, creating a very attractive share structure, and if you combine that with our plans for aggressive growth, a reverse split just doesn’t make sense to us. I look forward to updating our progress in the coming weeks.” 

 We have something big coming Subscribe Right Now!

Currently trading at a $784,827 market valuation WNRS os is 182,517,857 with 61,985,880 shares in the public float. The Company also has minimal debt on the books. WNRS has seen a significant surge in trading volume after WNRS reported the company decided to withdraw its application for a 1:20 reverse split of its common stock with FINRA. The Company withdrew the FINRA application considering its strategic expansion plans that include the increase of its product line and potential acquisitions that fit the company’s business model. This comes several days after the Winners executed an agreement with ClickStream Corp whereby Winners agreed to buy back 154,012,000 shares of Winners common stock owned by ClickStream for $160,265.63. This transaction reduces Winners outstanding shares of common stock from 336,529,857 to 182,517,857.   We will be updating on WNRS when more details emerge so make sure you are subscribed to Newsytrends.com by entering your email below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in WNRS either long or short and we have not been compensated for this article.

Houston Natural Resources, Inc. (OTCMKTS: HNRC) Heats Up as Oil & Gas Operator Reports Record Fiscal 2022 Financial Results and SPAC HNR Acquisition Corp Closes Deal

Houston Natural Resources, Inc. (OTCMKTS: HNRC) is making a big move up the charts since reversing off 52-week lows of $0.062. HNRC is a highly volatile stock that spiked to highs of $0.84 in December but collapsed over investor fears over lack of transparency. According to the Company they have an assets value of $1.14 per share and they recently reported unaudited record financial results for the year ending December 31, 2022. Total revenue for twelve months was $ 20,516,899 vs $ 18,217,737 in fiscal 2021, an increase of 12.6 % HNRC also earned a net income of $9,641,297 an unheard-of number on the bulletin boards and earnings per share of $0.14. The problem is the Company is not an SEC filer and these numbers are not audited otherwise this stock would not be trading anywhere near the current valuation of $6 million. 

HNRC has hired an accounting advisory firm to assist HNRC with a two-year current audited statement which will allow the company to apply for an up listing. The company has also signed an agreement with an underwriting firm to complete an up listing for HNRC on to a major exchange in 2023. Another exciting part of HNRC is the Company’s SPAC HNRAC Sponsors’ HNR Acquisition Corp which closed initial public offering listing on the NYSE with aggregate proceeds of $86,250,000 (NYSE:HNRA) HNR Acquisition Corp recently entered into a membership purchase agreement with Pogo Resources and two affiliates for a purchase price of $120 million dollars. Dallas-based Pogo acquires, develops, and exploits oil and gas assets in Texas’ Permian Basin. We will be updating on HNRC when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Houston Natural Resources, Inc. (OTCMKTS: HNRC) operating out of their executive offices in Houston, Texas, HNRC is a diversified energy company with oil and gas interests as well as wastewater treatment facilities. The Halff Oil Field in Crockett County, Texas, has 83 oil wells, with estimated 33 million barrels of oil and water treatment and appraised reserves of $69 million. The company has acquired a 9.9% interest in Cunningham Energy LLC with appraised reserves of $352 million. The company will also continue to seek new oil and gas and wastewater acquisitions as it focuses on creating more value for HNRC shareholders. According to Houston Natural Resources the Company has a net asset value (NAV) of $1.15 per share in appraised energy assets. HNRC intends to continue to pursue its long-term strategy of acquiring energy assets and providing additional dividends to shareholders in 2023. 

HNRC 100% owned subsidiary, HNR Oil Services LLC, is a Texas limited liability company, specializing in recycling and remediation of oil produced contaminates. HNR Oil Services will own and operate a licensed reclamation plant strategically located in south Texas. 

Houston Natural Resources, Inc formed HNRAC Sponsors. LLC and HNRAC formed HNR Acquisition Corp., a Special Purpose Acquisition Corporation. On February 11, 2022, HNRA closed its initial public offering listing on the NYSE with aggregate proceeds of $86,250,000 (NYSE: HNRA). HNRA is a newly organized blank check company formed for the purpose of effecting a business combination with one or more businesses. While HNRA may pursue an initial business combination target in any business or industry, it intends to focus on assets used in exploring, developing, producing, transporting, storing, gathering, processing, fractionating, refining, distributing, or marketing of natural gas, natural gas liquids, crude oil or refined products in North America.  

In January Houston Natural Resources, Inc, through its majority owned HNRAC Sponsors, LLC, sponsored SPAC HNR Acquisition Corp entered into a membership purchase agreement with Pogo Resources and two affiliates for a purchase price of $120 million dollars. Dallas-based Pogo acquires, develops, and exploits oil and gas assets in Texas’ Permian Basin. 

HNRA has an estimated $86 million in its current trust and the transaction is expected to provide $100 million in cash proceeds to Pogo, including a $15 million promissory note. The sellers are also to receive 2,000,000 common HNRA shares, and 500,000 shares are to be placed in escrow for HNRA’s benefit. Aside from these shares, HNRA is to receive a 100% interest in Pogo Resources on the first day of the calendar month that is four months prior to the deal’s close. 

In October, HNRA entered into a common stock purchase agreement with White Lion Capital, under which White Lion Capital could be directed to purchase up to $150 million in newly issued shares of the combined company between close and December 31, 2025. 

HNRC previously announced its strategy will result in an additional dividend to its shareholders, after the lock up period has expired, on its SPAC investments. This would provide a potential additional dividend for Houston Natural Resources Corp.’s (OTC: HNRC) shareholders in 2023. Houston Natural Resources Corp. (OTC: HNRC) intends to continue to pursue its long-term strategy of acquiring energy assets and providing additional dividends to shareholders in 2023 and currently has a net asset value (NAV) $1.15 per share in appraised energy assets. 

The Company is led by Frank Kristan who has more than 30 years of experience in the financial services industry. He became the President of Ludvik Capital, Inc and its successor Ludvik Holdings, Inc in 2005 that provides advisory services to private and public companies and is focused on making investments to increase revenues and portfolio value. He was also formerly the President and CEO of Patriot Advisors, Inc. primarily on companies in the energy, technology, telecommunications and internet related industries.

To Find out the inside Scoop on HNRC Subscribe to Newsytrends.com Right Now by entering your Email in the box below

HNRC

HNRC also owns 9.9% of Cunningham Energy; an independent producer of oil and gas based in Charleston, West Virginia. The company was formed in 2008 for the purpose of acquiring, exploring, and producing oil and gas in the Appalachian, Illinois, and Williston Basins. Since its inception the Company has relied on past experience in parallel with the application of new technologies to succeed in the ever changing field of efficient energy production. Cunningham Energy is positioned to take advantage of current and future trends in oil and natural gas production throughout these basins with aggressive but responsible decisions in the coming future and holds appraised reserves of $352 million. http://www.cunninghamenergy.com 

The Company’s subsidiary Worldwide Diversified Holdings, Inc. is focused on using a public trading vehicle, to acquire ownership positions in small to middle market companies over the next three years. The operations will provide for income from advisory services, interest, dividends and capital gains from investments in public and private companies in diversified industries worldwide. www.wdhinc.net 

In February HNRC hired an attorney to file an SEC registration statement on behalf of its subsidiary Worldwide Diversified Holdings, Inc (“WDHI”) for a public listing. The anticipated target listing price will be $3.50 per share. The shares in the previously announced spin-off of the non-energy assets included in the dividend program will be registered for trading on the open market. With a target listing of $3.50 per share, each HNRC shareholder will be issued one WDHI common share for every two HNRC common shares that were shareholders of record on December 16, 2022, equivalent to a $ 1.75 per HNRC common share stock dividend. 

On December 5, 2022, HNRC filed the corporate action for review by FINRA to allow the company to issue the stock dividend of one WDHI shares for every two shares of HNRC held by the shareholder on the record date. FINRA has responded and HNRC has been consistently corresponding to complete this review process. The company will continue to keep its shareholders informed regarding this dividend event. 

HNRC has hired an accounting advisory firm to assist HNRC with a two-year current audited statement which will allow the company to apply for an up listing. The company has also signed an agreement with an underwriting firm to complete an up listing for HNRC on to a major exchange in 2023. The $10 million dollar underwriting commitment for working capital to fund current operations, expansion and acquisitions. According to HNRC the Company is focused on realizing the value on the total of $1.15 per share in current appraised energy assets held by its subsidiaries for the benefit of the shareholders and is evaluating additional acquisitions in the energy and energy services industry to provide value for shareholders. 

On March 7 HNRC reported record financial results for the year ending December 31, 2022. Total revenue for twelve months was $ 20,516,899 vs $ 18,217,737 in fiscal 2021, an increase of 12.6 % HNRC also earned a net income of $9,641,297 an unheard of number on the bulletin boards compared to a net income of $7.6 million in fiscal 2021. HRNC reported Earnings per share for twelve months was $ 0.14 per share. 

Frank Kristan, President of Houston Natural Resources Corp commented that: “We are delighted that our growth is continuing with strong results reported for the year ending December 31, 2022. The company’s increase in revenues and earnings has been due to acquisitions and an increase in services it provides to its portfolio companies. The company sponsored a successful $86 million NYSE listing of an energy focused special purpose acquisition corporation in 2022 and acquired an interest in Cunningham Energy. We anticipate consistent growth from revenue and profit in 2023 in addition to other liquidity events for HNRC shareholders. The company is evaluating sponsoring other energy focused special purpose acquisition corporations in addition to water treatment plants, oil and gas assets and energy services opportunities.”

 For More on HNRC Subscribe Right Now!

Currently trading at a $6 million market valuation HNRC os is 74,696,433 with around 4,183,515 shares in the public float according to OTCMarktes. According to the Companys unaudited financial statements they have $92 million in assets and are virtually debt free with just $1 million in liabilities on the books. As we described above HNRC has a ton going for it and if they can successfully get their books audits and become an SEC filer that current valuations will be history. According to HNRC multiple press releases they have an assets value of over $1 per share and earned a net income of $9.6 million in fiscal 2022. Not only that they are the majority owner of a NYSE SPAC which recently entered into a membership purchase agreement with Pogo Resources and two affiliates for a purchase price of $120 million dollars. Dallas-based Pogo acquires, develops, and exploits oil and gas assets in Texas’ Permian Basin. We will be updating on HNRC when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in HNRC either long or short and we have not been compensated for this article.

Springbig Holdings Inc (NASDAQ: SBIG) Big Run Back Over $1 as Anticipation for Q4 and Fiscal 2022 Results Builds (Q4 and Fiscal 2022 Results Coming Thursday at Close)

Springbig Holdings Inc (NASDAQ: SBIG) is making a big move up the charts from the mid $0.70’s range where we first covered the stock last week to recent highs of well over $1 per share. Volume has picked up significantly as well as we are now just 2 days away from Q4 and fiscal 2022 financial results. As we noted in our last article on SpringBig; the Company continues to see rapid growth in revenues and is expanding its industry leading platform into dynamic new industries. Adding fuel to the fire is the fact that SBIG currently trades a fraction of its $6 IPO price from just a year ago and the CEO and Chairman of Springbig, Jeffrey Harris has been quietly purchasing more stock at recent price levels recently acquiring another 60,000 shares. In late 2022 SBIG fell well below $1 as the Cannabis industry markets experienced industry specific headwinds. However, SBIG has been coming back with power in 2023, rocketing back over $1 as the Company’s top line growth continues to accelerate resulting in record Q3 results and a new milestone of positive EBITDA being achieved this year. 

Expectations are high as we are just 2 days away from Q4 and fiscal 2022 financial results; SpringBig recently implemented cost cutting measures that are expected to result in approximately 21% less than annualized operating expenses incurred during 2022, shortening the timeline to Springbig’s goal of positive EBITDA this year. The Company beat expectations by 6.5% in Q3 and judging by the recent action in the stock price leading up to Thursday, investors are speculating on even better Q4 and fiscal results. The Company will also host a conference call to discuss the financial results on the same day at 5:00 p.m. ET. Participants can register at this link to receive a dial-in number and unique PIN. The webcast will be archived for one year following the conference call and can be accessed on Springbig’s investor relations website at https://investors.springbig.com/. According to SBIG revenues in fiscal 2022 are expected to come in at $27 to $28 million. For fiscal year 2023, Springbig expects an acceleration in top line growth, with the milestone of positive EBITDA being reached during fiscal 2023. We will be updating on SBIG when more details emerge so make sure you are subscribed to wwallstreet.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Springbig Holdings Incspringbig (NASDAQ: SBIG) is a market-leading software platform providing customer loyalty and marketing automation solutions to cannabis retailers and brands in the U.S. and Canada. springbig’s platform connects consumers with retailers and brands, primarily through SMS marketing, as well as emails, customer feedback system, and loyalty programs, to support retailers’ and brands’ customer engagement and retention. springbig offers marketing automation solutions that provide for consistency of customer communication, thereby driving customer retention and retail foot traffic. Additionally, springbig’s reporting and analytics offerings deliver valuable insights that clients utilize to better understand their customer base, purchasing habits and trends. SpringBig has assembled a top-level executive management team who have decades in the industry. Check SBIG management team out here. 

Springbig is no newcomer to loyalty marketing, our founders have over 20 years of experience in creating loyalty rewards programs for retail businesses. In fact, they were some of the original pioneers of retail loyalty marketing. CEO, Jeffrey Harris founded InteQ over 20 years ago, a company that took loyalty marketing from simple punch card programs in coffee shops to technologically advanced marketing tools at the forefront of some of the country’s biggest companies. Companies like Adidas, Reebok, and Citi Bank. After years of experience in big-box retail, our founders saw tremendous opportunity in the underserved cannabis industry and decided to bring advanced loyalty programs, an essential marketing tool in such a competitive industry, to cannabis dispensaries and brands. 

SBIG has seen rapid growth in revenues; in November the Company reported financial results for the second quarter ended September 30, 2022. Total revenue in the third quarter of 2022 increased to $7.4 million, up 22% from the third quarter of 2021 and up 13% from the second quarter of 2022. Subscription revenue increased 48% from the third quarter of 2021 and was up 9% from the second quarter of 2022. SpringBig had an adjusted EBITDA loss for the third quarter of $3.5 million as compared to a loss of $(1.2) million from the prior year period. Basic net income loss per share was $(0.12) based on 25.6 million weighted average shares outstanding.  

For full fiscal year 2022, Springbig expects revenue in the range of $27.0 – $28.0 million, representing 14% year-over-year growth at the midpoint. For fiscal year 2023, Springbig expects an acceleration in top line growth, with the milestone of positive EBITDA being reached during fiscal 2023. 

At the time of the Q3 announcement: 

SBIG CEO Jeffrey Harris stated: “Our third quarter results reinforce my view that we are widening the gap as the leading technology loyalty platform across the cannabis sector. Acknowledging that cannabis end-markets are experiencing industry specific headwinds, it’s absolutely clear to me that our growth trajectory is intact as we continue to leverage the network effect flywheel between retailers and brands, and that we are making the right investments to capture the long-term opportunity in front of us.” 

Paul Sykes, springbig’s CFO, added, “Looking to 2023, we expect the continuing strong growth in subscription revenue, increasing brands adoption and the emergence of data sales and other initiatives to drive top line acceleration, and we are reaffirming our goal of reaching the milestone of positive EBITDA during 2023.” 

SpringBig got its start in the cannabis industry however the Company’s software and solutions are easily expandable into many new industries. SBIG offers: 

Dispensary loyalty programs – loyalty rewards programs are the most effective way to build customer loyalty, increase foot traffic, and boost sales for cannabis dispensaries. By rewarding customers with points for every purchase, you’re guaranteed to increase customer retention, keep customers satisfied and turn one-time shoppers into your most loyal customers. 

To Find out the inside Scoop on SBIG Subscribe to wwallstreet.com Right Now by entering your Email in the box below

SBIG

Dispensary text message marketing – dispensary text message marketing is the easiest and most cost-effective marketing channel for cannabis businesses to advertise to potential customers. By using our FCC compliant dispensary marketing tools to gain insights into each of their customer personas, cannabis businesses are able to better target their customers and personalize their experiences for better results and guaranteed ROI. 

Cannabis CRM – our cannabis CRM gives you the unique data points required to operate a cannabis dispensary that non-cannabis CRM systems simply can’t provide. When used with our dispensary loyalty rewards & text message marketing platform, it becomes as simple as a few clicks to create targeted dispensary marketing campaigns based on real-time data insights into your inventory. 

Cannabis advertising network brands by Springbig is an advertising network unique to the cannabis industry that connects cannabis brands directly to consumers by giving your cannabis brand already on the shelves the ability to send sponsored text message marketing campaigns through Springbig’s network of retail cannabis businesses. 

Dispensary referral program software leverage word-of-mouth advertising by generating unique trackable links that your champion customers can share with their friends, family, and followers, on social media and of course sms, rewarding them for referring new customers to your dispensary and more importantly – buying your products. 

In February SBIG introduced a new integration with Flowhub, the leading cannabis software company for dispensaries. The Company’s latest feature utilizes Flowhub’s Maui™ to simplify the checkout process, allowing customers to track their rewards on the go or in store. 

Springbig and Flowhub’s two-way integration is immediately available to all dispensaries using both platforms and to current and incoming springbig loyalty members. The collaborative feature eliminates the need for customers to use their phones at checkout to redeem or track their rewards and offers. Instead, budtenders and dispensary employees can redeem springbig rewards for customers through point of sale. Additionally, budtenders and dispensary employees will have the ability to enroll customers in the loyalty program at checkout. The integration simplifies the rewards experience for budtenders and loyalty members and allows customers to interact with the rewards program however they choose. Customers also have the autonomy to track and engage with the rewards program through their personal devices when they are on the go and in the dispensary. 

Flowhub is the latest company to collaborate with springbig to introduce a forward-thinking integration for cannabis retailers and consumers. Previously, the Company partnered with KORONA POS to launch a bidirectional integration allowing merchants to apply and award loyalty offerings directly from KORONA POS at checkout.  

Jeff HarrisOn March 6 SpringBig announced Jeffrey Harris, CEO and Founder, and Paul Sykes, CFO, will participate in a fireside chat at the 35th Annual Roth Conference to be held at the Ritz Carlton, Laguna Niguel in Dana Point, California from March 12-14, 2023. The company’s presentation will begin at 1:30 pm PT on Monday, March 13, 2023.the presentation will be available on the Investor Relations section of the Company’s website . An online replay of the webcast will be available for 90 days afterward. The Company will also be participating in one-on-one and small group meetings. 

 We have something big coming Subscribe Right Now!

Currently trading at a $23 million market valuation SBIG os is 26,211,914 shares issued and outstanding. Trading on the NASDAQ and once again over $1 SBIG has a strong balance sheet with $14.9 million in assets and $6.9 million cash in the treasury and $14.8 million in liabilities. This is an exciting time for SBIG as the stock rockets back over $1 as the Company continues to see rapid top line growth. Expectations are high as we are just 2 days away from Q4 and fiscal 2022 financial results; SpringBig recently implemented cost cutting measures that are expected to result in approximately 21% less than annualized operating expenses incurred during 2022, shortening the timeline to Springbig’s goal of positive EBITDA this year. The Company beat expectation by 6.5% in Q3 and judging by the recent action in the stock price leading up to Thursday, investors are speculating even better Q4 and fiscal results. We will be updating on SBIG when more details emerge so make sure you are subscribed to wwallstreet.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in SBIG either long or short and we have not been compensated for this article.

China Dongsheng International, Inc. (OTCMKTS: CDSG) Heats Up as Co Reports Positive Soil Geochemical Results at its Titan 1 & Titan 2 Lithium Properties (Name Change to Titan Lithium, Inc.)

China Dongsheng International, Inc. (OTCMKTS: CDSG) is making a big move up the charts in recent days starting off around $0.03 on Wednesday of last week the stock recently surpassed $0.10 hitting an intraday high of $0.127. A low floater with just over 2 million shares in the public float, CDSG has quickly attracted some of the top players in small caps who are heavily accumulating at current levels. On Monday the stock was up over 40% as off 2pm on well over 2 million shares traded. CDSG is a sister stock to BRLL, a stock with a storied history of big moves on the bulletin boards. 

The big move up on CDSG comes after the Company recently reported positive geochemical results indicating lithium values ranging from 100 ppm to highs of 13,000 ppm at its Titan 1 project. Craig Alford, MSc, PGeo, and CEO of the Company, a Qualified Person under NI 43-101, noted “The results from the initial geochemical sampling are staggering. The size and strength of the Lithium anomaly at Titan 1 is particularly exceptional as it is within an area that has had no previous exploration. This comes after CDSG recently announced it is changing its name to Titan Lithium. We will be updating on CDSG when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

China Dongsheng International, Inc. (OTCMKTS: CDSG) through its wholly owned subsidiary Titan Lithium, Inc., is a lithium explorer and developer with operations in Nevada, USA and The United Republic of Tanzania. The Company recently reported it is applying for a name change to Titan Lithium, Inc. The name change will reflect the company’s lithium focus. The Company has a new twitter handle to: @TitanLithiumInc 

The West End Lithium Project is a world-class, shallow lithium deposit located in a low-risk jurisdiction just outside of Tonopah, Nevada. CDSG Lithium has partnered with Barrel Energy Inc. to utilize the company’s highly innovative lithium extraction methodologies designed for clay-hosted deposits. The WEL site, comprised of 24 unpatented lode claims, is strategically located directly adjacent to the TLC Lithium-in-clay project. Surficial rock samples from the TLC project have reportedly shown widespread lithium held in the sediments that have achieved results of up to 1300-2200 ppm. The TLC resource’s 8.83 Mt LCE measured and indicated resource now stands well above Nevada’s multi-billion-dollar Thacker Pass Lithium project, which holds 3.13 Mt of proven and probable LCE reserves. 

The Titan 1 project is centered over a large, sparely vegetated, flat lying ‘playa’ covering over sixty square miles (155 square kilometers). The basin is reportedly filled with a sequence of sediments and volcanics and has a thin alluvium cover. The area is morphologically and depositionally comparable to the mudstone/claystone projects of the southwest U.S., being very similar to the company’s WEL project claim area, the TLC project and the Thacker Pass projects of Nevada. The main target at Titan 2 is a dry lake bed and is an Endorheic Basin, meaning it has no outflow. Over time this basin has likely be the repository for a vast area of volcanic ash collection stemming from the volcanic activity to the north. The dry lake measures approximately 11.5 square miles (30 sq kms) in size and initial sampling of the Titan 2 prospect has returned high value Lithium within the surface sampling of up to 9,000 ppm (1.93% Li2O). A second round of sampling of the Titan 2 prospect was performed via equal grid spacing and we are awaiting the results. 

The Company recently reported positive soil geochemical sampling results from the first phase of the company’s extensive Titan 1 lithium property in Tanzania; positive geochemical results indicated lithium values ranging from 100 ppm to highs of 13,000 ppm. Craig Alford, MSc, PGeo, and CEO of the Company, a Qualified Person under NI 43-101, noted “The results from the initial geochemical sampling are staggering. The size and strength of the Lithium anomaly at Titan 1 is particularly exceptional as it is within an area that has had no previous exploration and both sample lines ended at their northern limit within some of the highest grades of up 2.79% Li2O. These very strong results are being followed up by ongoing sampling and exploration on the Titan 1 Project area.” More results will be announced in the coming weeks. 

  • Lithium values ranging from 100 ppm to highs of 13,000 ppm
  • Within the central line, the first line run on the project, the positive Li values averaged 0.55% Li2O (2,569ppm Li) over 7.4 miles (12 km)
  • A parallel line, 1.8 miles east of the central line was run and returned positive values of 1.14% Li2O (5,300ppm Li) over 3.7 miles (6 km)
  • Values for sodium, potassium, magnesium broadly mirror and confirm the distribution of the anomalous lithium values. Potassium oxide (K2O) values ranged as high as 3.6% in the results
  • Additional samples have now been collected on lines that have now extended the original described two both to the north and south, as well as new lines run parallel that should assist in defining the Titan 1 massive Lithium anomaly
  • For the Titan 2 prospect, just one 0.8 miles (1.3km) long line of soil samples was originally collected
  • Results from the Titan 2 line averaged 2,930ppm Li, the lowest value returned 800ppm and the highest value, located at the end of the line returned 9,200 ppm (1.98% Li2O)

ImageIn January the Company brought on mining executive and professional geoscientist Mr. Craig Alford as a Chief Executive Officer. Mr. Alford has been responsible for budgeting and the expenditure of hundreds of millions of dollars and developed economic analysis for large M & A transactions. Mr. Alford’s tenure as Deputy General Manager with the Zijin Mining Group resulted in large investments in Pretium Resources, Kyrgyzstan’s Taldybulak Gold Mine, Norton Gold in Australia, Barrick Gold’s Porgera mine and Ivanhoe Mines’ Kamoa Copper Project. During this crucial time for the battery metal sector, Mr. Alford has been involved in a number of base metal and lithium exploration projects key to the industry. 

To Find out the inside Scoop on CDSG Subscribe to Newsytrends.com Right Now by entering your Email in the box below

CDSG

CDSG TO ACQUIRE 100% INTEREST IN LITHIUM PROJECT IN TANZANIA | User WallsThe Company also recently entered into a Definitive Agreement with Kilimanjaro Lithium Inc., a private corporation, whereby CDSG will have the exclusive right to earn up to a One Hundred Percent (100%) interest in several Prospecting Licences (PLs) that make up two large projects in The United Republic of Tanzania. Tanzania is presently experiencing attention and investment into Lithium exploration from numerous companies, including Liontown Resources. Recently, the U.S announced it has entered into a Memorandum of Understanding (“MOU”) for critical battery minerals with several African nations.   

The Tanzanian projects, which cover more than 150 square miles, will greatly add to the company’s portfolio. The company will acquire an immediate 80% interest in the PL’s by issuing 133 million common shares (at a deemed value of $6,650,000). After CDSG has attained this initial 80% ownership, the Company shall be responsible for exploration and development expenditures and shall make cash payments totaling $350,000.00 over the next 9 months. To attain the final 20% interest in the Properties, CDSG will make further payments of $1,000,000 for each additional 5% interest for the full 100% interest for an aggregate payment of $4,000,000 of additional payments. A 3% Net Smelter Return (“NSR”) on production of the Properties has been retained by the Licensor, however, CDSG has the exclusive right to purchase up to 2% of the NSR for $1,000,000 per 1%, for an aggregate of up to $2,000,000. 

On March 6 CDSG announced positive soil geochemical sampling results from an initial sampling phase of the company’s expansive Titan 2 lithium property in Tanzania. The Titan 2 project is located approximately 20 miles west of the Titan 1 claim group and is centered over a large, flat lying area of approximately 23 square miles (60 square kilometers). As part of the preliminary prospecting work on the project one line of surficial geochemical soil sampling was conducted over a length of 0.8 miles (1.3kms).\ 

Results from the line averaged 3,930 ppm Lithium. The lowest value returned 800 ppm Li and the highest value, located at the end of the line, returned 1.98% Li2O (9,200 ppm Li). Values for other elements broadly mirror and confirm the distribution of the anomalous lithium values. 

Craig Alford - Director and Interim CFO - China Dongsheng International Inc | LinkedInCraig Alford, MSc, PGeo, and CEO of the Company, a Qualified Person under NI 43-101, noted “The results from this initial prospecting sampling were extremely impressive. Much like Titan 1, our end of line samples returned the highest grade. Our field team has now returned to the site to follow up on the strong Lithium results by employing a sample grid over a much larger area that is roughly 2.5 miles by 2 miles in size.” 

 For More on CDSG Subscribe Right Now!

Currently trading at a $19 million market valuation CDSG os is 231,776,927 and the Company has just 2,388,960 shares in the public float. CDSG which is in the process of changing its name to Titan Lithium is at the right place at the right time as North America’s capacity for battery cell production will likely grow more than tenfold in the coming five years and there is a deficiency of production. CDSG has already made a number of significant discoveries including positive geochemical results indicated lithium values ranging from 100 ppm to highs of 13,000 ppm at its Titan 1 project as well as positive soil geochemical sampling results from an initial sampling phase of the company’s expansive Titan 2 lithium property in Tanzania. Results from the line averaged 3,930 ppm Lithium. The lowest value returned 800 ppm Li and the highest value, located at the end of the line, returned 1.98% Li2O (9,200 ppm Li). Values for other elements broadly mirror and confirm the distribution of the anomalous lithium values.We will be updating on CDSG when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in CDSG either long or short and we have not been compensated for this article.